Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Astellas Pharma Inc.
DescriptionAnti CD40 human mAb
Molecular Target CD40
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationOrgan transplant rejection
Indication DetailsPrevent organ transplant rejection
Regulatory Designation
PartnerKyowa Hakko Kirin Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today